Preferred Label : ublituximab;

UNII : U59UGK3IPC;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3578966/fr/briumvi-ublituximab-sclerose-en-plaques
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
ublituximab
adult
infusions, intravenous
evaluation of the transparency committee
multiple sclerosis, relapsing-remitting
ublituximab

---
https://www.ema.europa.eu/en/medicines/human/EPAR/briumvi
2023
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
ublituximab
ublituximab
ublituximab
drug approval
europe
adult
multiple sclerosis, relapsing-remitting
infusions, intravenous
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
antigens, CD20
drug evaluation, preclinical

---
Nous contacter.
24/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.